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Immune Response to ADT and GVAX in Localized Prostate Cancer 
 
Statement of Translational Relevance: 
In preclinical models of prostate cancer, androgen deprivation therapy (ADT) promotes 
immunogenic cell death, transiently mitigates T cell tolerance to tumors and augments 
vaccine-induced antigen-specific CD8+ T cell responses. However, there are limited data 
on the immunologic effects of ADT on the tumor microenvironment (TME) in patients.  
In a neoadjuvant trial, we treated men with high-risk localized prostate cancer with either 
ADT or ADT plus low-dose cyclophosphamide and a cell-based vaccine (Cy/GVAX), 
prior to radical prostatectomy. ADT induced a complex immune cell infiltrate and 
increased intratumoral cytolytic CD8+ T cells.  However, this CD8+ T cell increase was 
accompanied by a proportional increase in FoxP3+ regulatory T cells (Tregs), proving 
strong evidence for adaptive Treg resistance. When given prior to surgery, Cy/GVAX 
modestly augmented the immunologic effects of ADT and decreased disease recurrence 
compared to ADT alone. These data support the observation that ADT has pro-
inflammatory effects. However, these antitumor effects appear to be counterbalanced by 
a proportional increase in local immunosuppression.  
 
Abstract:  
Purpose: Previous studies suggest that androgen deprivation therapy (ADT) promotes 
antitumor immunity in prostate cancer. Whether a vaccine-based approach can augment 
this effect remains unknown. 
 
Experimental Design: Therefore, we conducted a neoadjuvant, randomized study to 
quantify the immunologic effects of a granulocyte-macrophage colony-stimulating factor 
(GM-CSF)-secreting allogeneic cellular vaccine in combination with low-dose 
cyclophosphamide (Cy/GVAX) followed by degarelix versus degarelix alone in patients 
with high-risk localized prostate adenocarcinoma who were planned for radical 
prostatectomy. 
 
Results: Both Cy/GVAX plus degarelix and degarelix alone led to significant increases in 
intratumoral CD8+ T cell infiltration and PD-L1 expression as compared to a cohort of 
untreated, matched controls. However, the CD8+ T cell infiltrate was accompanied by a 
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proportional increase in regulatory T cells (Treg), suggesting that adaptive Treg 
resistance may dampen the immunogenicity of ADT. Although Cy/GVAX followed by 
degarelix was associated with a modest improvement in time-to-PSA progression and 
time-to-next treatment as well as an increase in PD-L1, there was no difference in the 
CD8 T-cell infiltrate as compared to degarelix alone. Gene expression profiling 
demonstrated that CHIT1, a macrophage marker, was differentially upregulated with 
Cy/GVAX plus degarelix compared to degarelix alone. 
 
Conclusions: Our results highlight that ADT with or without Cy/GVAX induces a 
complex immune response within the prostate tumor microenvironment. These data have 
important implications for combining ADT with immunotherapy. In particular, our 
finding that ADT increases both CD8+ T cells and Tregs, supports the development of 
regimens combining ADT with Treg-depleting agents in the treatment of prostate cancer.  
  
Introduction: 
Prostate cancer remains the second most common cause of cancer-related mortality in 
men and definitive local therapy represents the only treatment modality with the potential 
for cure.
1
 Despite advances in surgical approaches, patients with high-risk localized 
prostate cancer continue to have a high likelihood of disease recurrence following 
definitive local therapy.
2,3
 To date, no neoadjuvant therapy preceding prostatectomy has 
demonstrated sufficient efficacy to warrant FDA approval.  
 
In contrast to traditional therapies which decrease tumor bulk prior to surgery, 
immunotherapy has the potential to re-engage systemic anti-tumor immune responses, 
thereby eradicating distant micro-metastases. Although the development of sipuleucel-T 
for castration-resistant prostate cancer (CRPC) demonstrated the potential for 
immunotherapy in prostate cancer, immune checkpoint inhibitors have not yielded 
significant responses, except perhaps when used in combination.
4-10
 One significant 
challenge to inducing anti-tumor immunity in prostate cancer is the non-inflamed tumor 
microenvironment (TME).
11
 Prostate tumors also generally have a low mutational burden 
and low PD-L1 expression; these factors predict response to immunotherapy in other 




 In addition, prostate tumors demonstrate multiple mechanisms of 
immune escape including defective antigen processing, decreased MHC class I 
expression, and infiltration with regulatory T cells (Tregs), myeloid-derived suppressor 




Prostate GVAX is an allogeneic cell-based prostate cancer vaccine composed of two 
irradiated cell lines (PC3 and LNCaP) that have been genetically modified to secrete 
granulocyte-macrophage colony-stimulating factor (GM-CSF).
14
 The release of GM-CSF 
by these modified tumor cells promotes the recruitment of dendritic cells and subsequent 
presentation of tumor antigens to T-cells with associated activation of anti-tumor immune 
responses. Prior randomized controlled trials of GVAX as monotherapy or in 
combination with docetaxel in mCRPC failed to show a survival benefit over 
chemotherapy, suggesting that allogeneic cell-based immunotherapy may be insufficient 
on its own to generate a robust T cell response against prostate cancer.
14
 This may be 
particularly relevant in advanced metastatic CRPC, wherein a more immunosuppressive 
TME predominates.
15
 However, preclinical studies demonstrate that administering low-
dose cyclophosphamide prior to a cell-based GM-CSF-secreting vaccine can increase 
CD8+ T cell infiltration in the prostate, and transiently deplete regulatory T cells 
(Tregs).
16,17
 These preclinical data are supported by clinical trials combining GVAX with 





In addition, prior studies in murine models show that castration results in de novo 
presentation of prostate-restricted antigens in tumor-draining lymph nodes, with transient 
mitigation of T cell tolerance.
18
 ADT can also induce a pro-inflammatory immune cell 
infiltrate, supporting the hypothesis that androgen ablation may augment vaccine-induced 
effector T cell responses, particularly during the peri-castration period.
18
 Whether similar 
immune modulation occurs in patients remains poorly understood.  
 
To address these questions, we conducted a randomized neoadjuvant study to test the 
hypothesis that the combination of low-dose cyclophosphamide plus GVAX (Cy/GVAX) 
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could augment the ADT-induced immune response in men with localized high-risk 
prostate cancer. The LHRH antagonist degarelix acetate was selected as ADT for this 
study based on its rapid onset-of-action allowing shorter time-to-surgery, lack of transient 
increase in testosterone reducing risk of tumor flare, and the observation that degarelix 
leads to a robust immune cell infiltrate in pre-clinical models, peaking around 2 weeks 
after administration
18
. A secondary endpoint of the study was to test whether ADT plus 
Cy/GVAX prolongs time to PSA recurrence as compared to ADT alone. We also sought 
to more deeply profile the immunological changes in the prostate TME mediated by ADT 
with or without Cy/GVAX.  
 
Patients and Methods: 
Patients  
Men with intermediate to high-risk localized prostate adenocarcinoma, defined as clinical 
stage T1c-T3b, N0, M0 and a Gleason sum ≥ 4+3 (grade group ≥3) in at least two cores 
were considered eligible if they were planning to undergo prostatectomy. All patients 
were required to have an Eastern Cooperative Oncology Group performance status of 0 
or 1; and normal kidney, liver, and marrow function. Patients with nodal (N1) or distant 
(M1) metastases were excluded. Key additional exclusion criteria included prior 
immunotherapy or vaccine therapy for prostate cancer, prior radiation, hormonal, or 
chemotherapy, autoimmune disease requiring corticosteroids, or known allergy to 
cyclophosphamide or G-CSF/GM-CSF. Written informed consent was obtained from all 
patients, and studies were conducted in accordance with the U.S. Revised Common Rule 
and approved by Institutional Review Board.  
 
Study Design and Treatment 
Patients were randomized 1:1 to degarelix alone (240 mg subcutaneously) versus 
cyclophosphamide (200 mg/m2 intravenously) and GVAX (2.5×10
8
 PC3 cells, 1.6×10
8
 
LNCaP cells) given 2 weeks before degarelix.  Randomization was stratified by Gleason 
sum: ≤7 vs 8-10. All patients underwent radical prostatectomy 2 weeks after degarelix 
(Figure 1). Prostatectomy specimens were assessed for Gleason grade, nodal 
involvement, and pathological stage using standard methods. Following pathological 
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review of prostatectomy specimens, a tumor block was selected from the highest grade 
tumor located in the prostate and microtome sections were prepared for biological 
analysis of the TME, including immunohistochemical staining for CD8, FOXP3, and PD-
L1, with additional sections for expression profiling (Nanostring). In addition, a 
contemporaneous cohort of matched-controls (Cohort C) who did not receive any 
neoadjuvant therapy provided untreated radical prostatectomy tumor samples, which 
were compared to post-treatment prostatectomy samples from study Cohort A (degarelix 
alone) and Cohort B (Cy/GVAX plus degarelix) in genetic and immunohistochemical 
analysis. Patients were subsequently followed for biochemical (PSA) and metastatic 
disease progression.  
 
Outcomes:  
The co-primary endpoints of the trial were safety and CD8+ T cell density (CD8+ 
cells/mm
2
) in the prostate tumor tissue following neoadjuvant therapy. Safety was 
assessed using NCI Common Toxicity Criteria version 4.03. Secondary endpoints 
included feasibility, Treg density (FoxP3+ cells/mm
2
) in the prostate gland, CD8 to Treg 
ratio, time-to-PSA recurrence, time-to-next anti-cancer therapy, and time-to-metastatic 
progression. Time-to-PSA recurrence was defined as the interval from time of 
prostatectomy to the time when the PSA was ≥0.2ng/mL for the first of at least two serial 
rises in PSA (≥2 weeks apart). 
 
Immunohistochemistry 
CD8 staining was performed by steaming slides for 45 minutes in Dako Target Retrieval 
Solution (Agilent Technologies, Inc, Wilmington, DE), followed by incubation with a 
mouse anti-human monoclonal anti-CD8 antibody for 45 minutes at room temperature 
(Agilent Technologies, Inc, Wilmington, DE). For FoxP3 staining, slides were steamed 
for 45 minutes in Dako Target Retrieval Solution (Agilent Technologies, Inc, 
Wilmington, DE) and then incubated with a mouse monoclonal anti-FoxP3 antibody 
overnight at 4C (eBioscience, San Diego, CA, 1:250 dilution). For CD8, the secondary 
antibody used was the UltraVision Quanto Detection System HRP DAB (ThermoFisher, 
Waltham, MA). For Foxp3, the secondary antibody was the PowerVision+ kit (Leica 
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Biosystems, Buffalo Grove, IL). Staining was visualized using 3,3’-Diaminobenzidine 
(DAB) (Sigma, Saint Louis, MO, FAST 3,3’-Diaminobenzidine Tablets) and slides were 
counterstained with hematoxylin. For CD8 and Foxp3, IHC stained slides were scanned 
using an Aperio ScanScope CS. Sections for tumor for image analysis were performed 
using ImageScope by selecting regions of invasive carcinoma and carefully excluding 
regions in which inflammatory infiltrates involved benign glands. CD8 and Foxp3 cell 
data were obtained using positive IHC cell counting algorithms implemented in Aperio 
Spectrum software by applying Hue, Saturation and Brightness (HSB) color space. Cell 
numbers were normalized to the overall areas/region of interest and annotated a trained 
pathologist to provide cell density, which was assessed for each patient and compared 
across study arms. PD-L1 IHC staining and scoring was performed as previously 
described.
13
 Although some PD-L1 expression has previously been reported on immune 
cells in prostate cancer, such cells are morphologically identified as primarily 
macrophages; here we analyzed and report tumor-cell PD-L1 expression.  
 
Expression Profiling 
Immune gene expression in the prostate TME was profiled using the Nanostring IO360 
Immune Panel.
19
 Sufficient tissue for analysis was available from 13 patients from arm A 
(degarelix) and 12 patients from arm B (degarelix + Cy/GVAX) as well as 18 untreated 
matched-control patients. Nanostring count data were normalized by first thresholding to 
exceed mean + 1 standard deviation of negative controls, then scaling each sample by a 
positive control normalization factor to correct for total counts, and additionally, scaling 
with a set of pre-defined housekeeping genes, as described in the Nanostring 
documentation
20
. Three housekeeping genes (FCF1, POLR2A, and TUBB) were 
excluded from the normalization process due to high cross-sample variance, and two 
additional genes (CC2D1B and GUSB) were excluded due to poor correlation with other 
housekeeping genes. This scaling corrected for background noise and differences in total 
gene count across samples, allowing for differential gene expression between groups to 
be calculated by unpaired t-test. For each pairwise comparison, we performed Benjamini-
Hochberg multiple-testing correction and reported the number of differentially up-
regulated and down-regulated genes with a corrected p-value<0.05.  
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Nanostring data were used to computationally infer an absolute abundance of immune 
cell types in each sample in order to compare the two study arms with each other and 
with the untreated group. These analyses were performed using the CIBERSORT 
algorithm, which de-convolutes gene expression matrices to a mixture of known immune 
cell types by fitting to a validated reference matrix of 22 immune cell subtypes, where 
each cell subtype has a defined set of differentially expressed genes.
21
 This approach was 
limited by the fact that Nanostring profiles a limited set of targeted genes rather than the 
whole-transcriptome, so not all differentially expressed genes in the CIBERSORT 
reference matrix were captured. However, Nanostring specifically targets immune-related 
genes, and there are a significant number of differentially expressed genes captured for 
each immune cell subtype by the Nanostring panel. These are reported in Supplemental 
Table S1.  CIBERSORT was able to de-convolute immune cell composition from these 
genes with a p-value of <0.05 for 13 treatment arm A samples, 10 treatment arm B 
samples, and 12 untreated control samples.  
 
Statistical Analysis 
Our primary hypothesis was that men receiving Cy/GVAX followed by ADT would have 
a 2-fold (100%) increase in CD8+ T cell infiltration as compared to men receiving ADT 
alone. With 16 patients per arm, and assuming an 86% coefficient of variation for the 
average CD8+ T cell density, a one-sided 0.05 α-level t-test of the logarithms of these 
ratios would provide 82% power to detect a 2-fold (100%) increase in CD8+ T cell 
density between treatment groups. Thus, the trial was powered to recruit 32 patients, with 
a total of 29 patients ultimately recruited. The primary statistical endpoint of this study 
was CD8+ T cell density quantified by the number of nuclei of staining positive for CD8 
per mm2. Following a log transformation, the mean CD8+ T cell densities were 
compared between treatment arms using a two-way analysis of variance (ANOVA) with 
the stratification variable, Gleason score, treated as a block factor. Event time 
distributions for PSA recurrence, time to metastasis, and time to next cancer treatment 
were estimated with the method of Kaplan and Meier and compared using a stratified 
Cox proportional hazards model. For all comparisons of differential gene expression, t-
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tests were applied to the normalized Nanostring counts matrix, and p-values corrected for 
multiple testing by the Benjamini-Hochberg method. Similarly, t-tests with Benjamini-
Hochberg correction were applied to the inferred CIBERSORT immune cell abundance 
matrices, and to the IHC density values for CD8 and FOXP3. In a secondary analysis, 
hypothesis testing for unbiased association of clinical variables with time-to-PSA 
recurrence and time-to-next treatment was performed using multiple Cox regression with 
backward feature selection using the Akaike Information Criterion
26-28
, and visualized 
using hazard ratio forest plots and Kaplan-Meier survival curves. The same multiple Cox 
regression with backward feature selection was performed to test for association of 
clinical variables with metastasis and time to testosterone recovery (Figure S1). Pearson 
correlation was also calculated between all clinical, gene expression, and IHC variables 
as well as correlation of each variable with disease recurrence, visualized in Figure S2. 
Statistical analyses were performed using R version 3.5.3 and SAS version 9.2. 
 
Results: 
32 patients were recruited to the study with 16 randomized to each arm. 1 patient 
randomized to degarelix alone and 2 patients randomized to degarelix plus Cy/GVAX 
withdrew consent before study drug initiation. Therefore, 29 patients received study 
treatment. 15 patients received  degarelix alone and 14 received degarelix plus Cy/GVAX 
(one patient in this group withdrew following cerebrovascular ischemia, and was 
subsequently lost to follow-up). Clinical characteristics of the two treatment groups were 
similar with respect to age, risk status, Gleason sum, tumor stage, regional nodal 
involvement, and surgical margins (Table 1). 64% of patients had Gleason ≥8 disease, 




Both degarelix alone and degarelix plus Cy/GVAX were well-tolerated. A single grade 3 
ALT elevation was reported in the degarelix plus Cy/GVAX group, with no other 
treatment-related grade 3 or 4 adverse events reported (Table 2). All enrolled patients 
successfully underwent radical prostatectomy, with no significant unexpected surgical 
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complications or toxicities reported. Significant surgical complications were defined as 
blood loss in excess of 2500mL, operative time in excess of 3.5 hours, hospital stay in 
excess of 4 days or systemic symptoms including fever, rash or myelosuppression.  
 
Degarelix (ADT) Induces CD8 T Cell Infiltration with a Proportional Increase in Tregs  
Prostatectomy samples from both treatment arms, degarelix and degarelix + Cy/GVAX, 
showed significantly increased intratumoral CD8+ T cell density by IHC as compared to 
untreated matched controls (Figure 2C). However, this CD8 infiltration was balanced by 
a proportionally increased infiltration with Tregs, such that the CD8/Treg ratio remained 
consistent across all treatment groups (Figure 2D, 2E). While there was a significant 
increase in both CD8+ T cell and Treg infiltrate with degarelix versus controls and 
degarelix + Cy/GVAX versus controls, there was no statistically significant difference 
between the degarelix and degarelix + Cy/GVAX treatment groups (Figure 2), suggesting 
that the GVAX vaccine did not induce additional CD8 infiltration in this setting as 
compared to degarelix alone. Since FOXP3 can potentially be expressed in other T-cell 
populations, we also analyzed our transcriptomic data to identify whether treatment led to 
increased expression of other Treg markers including GITR (TNFRSF18), CTLA-4 and 
CD25 (IL2RA). We observed increased expression of GITR, CTLA-4 and CD25 with 
both degarelix alone and degarelix plus Cy/GVAX compared to untreated controls 
(Supplemental Figure 3). However, there was no difference in expression of these 
markers between degarelix and degarelix plus Cy/GVAX. 
 
Increased PD-L1 Expression after GVAX Vaccination  
Consistent with prior reports, tumor cell PD-L1 expression was minimal in untreated 
patients (Figure 3). Degarelix alone appeared to modestly increase PD-L1 expression, 
consistent with the notion that cytokine secretion from infiltrating CD8+ T cells may 
drive up-regulation of immune checkpoints.  Tumor samples from patients treated with 
degarelix + Cy/GVAX were found to have increased PD-L1 staining compared to 
patients treated with degarelix alone, with a higher proportion of samples exceeding 5% 
PD-L1 positivity (Figure 3); this trend was not statistically significant. Although there 
appeared to be some areas of PD-L1 staining in inflammatory cells in the stroma, the 
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majority of cells staining positive for PD-L1 were tumor cells. Taken together, these data 
suggest that while the GVAX vaccine does not significantly increase CD8+ T cell 
density, the infiltrating immune cells induced by GVAX may be capable of promoting 
PD-L1 up-regulation.  
 
Degarelix and Degarelix plus Cy/GVAX Induce Complex Changes in Immune Gene 
Expression 
Pairwise differential gene expression was performed on normalized Nanostring data from 
prostatectomy samples, comparing untreated control patients, degarelix-treated patients, 
and degarelix + Cy/GVAX treated patients. This analysis identified 98 genes up-
regulated in both degarelix and degarelix + Cy/GVAX vs control (Figure 4A). CHIT1, a 
macrophage activation marker, was the only gene significantly up-regulated in degarelix 
+ Cy/GVAX vs degarelix (Figure 4B).
 22
 The CIBERSORT algorithm was used to de-
convolute and infer the abundance of immune cell subtypes in each sample from 
Nanostring gene expression. Fractional contributions of immune cell populations were 
then compared between treatment groups (Figure 4C). These data show that a complex 
immune infiltrate was present in these prostatectomy samples at time of surgery, with 
significant populations of B cells, CD4 T cells, M1 macrophages, M2 macrophages, and 
mast cells. Summing the inferred abundance of each cell type yielded a total immune 
infiltrate estimate from gene expression data. Those data showed that that total immune 
infiltrate was significantly increased in both degarelix and degarelix + Cy/GVAX 
compared to control, but not in degarelix + Cy/GVAX as compared to degarelix alone 
(Figure 4D). CIBERSORT analysis also revealed an increased infiltrate of CD8+ T cells, 
M2 macrophages, and gamma-delta T-cells in both treatment groups as compared to 
untreated controls, with a raw p-value < 0.05.  Although the CD8+ T cell increase is 
consistent with the IHC data (Figure 1), these differences based on gene-expression 
analysis were not statistically significant after adjustment for multiple testing (Figure 4E). 
To further assess whether treatment could increase T-cell activation, we evaluated 
interferon-γ and granzyme B expression levels and demonstrated no significant difference 
in expression levels between the treatment groups (Supplemental Figure 3). 
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Degarelix plus Cy/GVAX is Associated with Clinical Outcome  
At 24 months post-prostatectomy, 69% of patients were free of PSA recurrence in the 
Cy/GVAX plus degarelix treatment group as compared to 40% in the degarelix-only 
group (Table 1). Initial univariate cox regression of treatment group against time-to-PSA 
recurrence stratified by Gleason sum 7 versus Gleason sum greater than 7 yielded a 
hazard ratio of 0.44 (95% Confidence Interval 0.13-1.43, p = 0.17), with time-to-next-
treatment yielding a hazard ratio of 0.41 (95% Confidence Interval 0.13-1.36, p = 0.15). 
After determining informative clinical variables for prediction of time-to-PSA recurrence 
using backwards feature selection by the Akaike Information Criterion, multiple Cox 
regression was performed accounting for interactions between patient age, tumor stage, 
Gleason sum, and treatment group. Using this regression analysis, treatment with 
Cy/GVAX plus degarelix showed an increased time to PSA recurrence as compared to 
that observed in patients treated with degarelix alone, with a hazard ratio of 0.29 (95% 
Confidence Interval 0.08-1.00, p = 0.05) (Fig. 5A, 5B). Backward feature selection 
converged to the same set of clinical variables for prediction of time-to-next treatment, 
where there was a statistically significant treatment effect for degarelix plus Cy/GVAX 
compared to degarelix alone, with a hazard ratio of 0.26 (95% Confidence Interval 0.071-
0.97, p = 0.046) (Fig. 5C, 5D). There was no significant difference observed between the 
two treatment groups in prediction of time-to-metastasis, where backward feature 
selection converged to a null model, and univariate cox regression with treatment group 
yielded a p-value of 0.46 (Figure S1). This may be due to the overall low rate of 
metastases in this patient population, with only 5 cases of metastasis observed across the 
two treatment groups (Table 1). There was also no significant difference in time-to-
testosterone recovery between the two treatment groups (Figure S1), suggesting that the 
improved time to PSA recurrence cannot be accounted for by differences in the duration 
of a castrate level of testosterone. Correlation with recurrence is shown in Figure S2 for 
each variable considered in the first step of the backward feature selection model, such 
that CD8+ and FOXP3+ density as well as PD-L1 level were each negatively correlated 
with recurrence, but were not individually predictive of time-to-recurrence and were not 
additionally informative after accounting for treatment group, age, stage, and Gleason 
sum.  




This study demonstrates that neoadjuvant ADT (degarelix acetate) with or without the 
addition of GVAX immunotherapy and low-dose cyclophosphamide promotes a complex 
immune response within the prostate TME. Treatment was well-tolerated and did not lead 
to unexpected surgical complications, providing proof-of-concept for an immunotherapy-
based neoadjuvant approach to prostate cancer treatment. Importantly, we found that 
ADT significantly increases the intra-tumoral CD8+ T cell infiltrate in prostate cancer. 
However, our comprehensive analyses of the immune TME showed that ADT induces 
other important immunologic changes, with both pro-inflammatory and 
immunosuppressive effects. Perhaps most strikingly, we observed that the CD8+ T cell 
infiltrate was accompanied by a proportional increase in Tregs, a key immunosuppressive 
cell population that mediates immune resistance in multiple tumor types.
20
 The addition 
of cyclophosphamide, which has previously been shown to transiently deplete Tregs, did 
not appear to significantly deplete Tregs in this setting.  The addition of Cy/GVAX to 
ADT did lead to a modest increase in PD-L1 expression as well as a statistically 
significant increase in the macrophage marker CHIT1, perhaps suggesting increased 
immunologic activity for the combination therapy. When accounting for patient age, 
tumor stage and Gleason sum in a multiple regression model selected by unbiased AIC 
backward feature selection
26-28
, there were significant improvements in time-to-PSA 
recurrence and time-to-next therapy in patients treated with Cy/GVAX plus degarelix 
compared to degarelix alone, suggesting the possibility that the combination regimen has 
some clinical activity.    
 
Prior pre-clinical and clinical studies showed that androgen deprivation can re-model the 
immune TME in prostate tumors towards a pro-inflammatory state. Our group previously 
demonstrated in the MycCaP murine model that ADT initially leads to a pro-
inflammatory immune cell infiltrate in prostate tumors with increases in CD8+ T cells, 
Tregs, macrophages and NK cells.
18
 However, this infiltrate is transient and appears to 
dissipate with the emergence of castration-resistance. Other groups have also shown that 
androgen ablation can increase B-cell infiltration, which may promote progression to 
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castration-resistance through B-cell-derived lymphotoxin production.
21
 In patients, the 
androgen-receptor blocker flutamide was shown to induce T cell infiltration and increase 
expression of pro-inflammatory immune-related genes (interferon-ɣ, TNF-⍺, Granzyme 
A) in prostate cancers when given prior to prostatectomy.
22,23
 Several prior studies have 
also investigated the use of neo-adjuvant vaccine-based immunotherapy approaches to 
enhance anti-tumor immune responses. For example, the autologous cellular vaccine, 
sipuleucel-T, was shown to promote lymphocyte recruitment and enhance TH1 responses 




The findings reported here are largely consistent with these prior observations and 
suggest that ADT may prime prostate-specific T cell responses. We observed that ADT 
led to a robust increase in CD8+ T cells, which was not further enhanced by Cy/GVAX. 
One possible reason for the lack of further CD8+ infiltration with Cy/GVAX could be the 
allogeneic nature of the GVAX vaccine relative to the patients’ tumors. The vaccine cell 
line PC3 was originally derived from a skull metastasis, and LNCAP is originally derived 
from a lymph node metastasis, and it is possible that neither consistently shared tissue-
specific antigens with the primary prostate tumors in the treated patients. It may also be 
the case that GM-CSF was insufficiently able to activate dendritic cells, as it has been 
found that modified versions of GVAX expressing dendritic cell activating molecules 
such as STING were far more effective in preclinical models
30
. It should also be noted 
that the prostate cancer microenvironment is particularly immunosuppressive, such that 
CD8 T-cells isolated from the prostate remain refractory to stimulation even in ex vivo 
experiments
31
, indicating that improved depletion of Tregs may also improve response to 
GVAX. Of note, there was also increased PD-L1 expression with ADT, which did appear 
to be augmented by the addition of Cy/GVAX. The significance of this upregulation of 
PD-L1 is unclear but could reflect an adaptive response to interferon-ɣ produced by 
activated T-lymphocytes. Future mechanistic work is required to better understand this 
observation. Furthermore, and consistent with the hypothesis that counter-regulatory 
mechanisms can function to maintain immune evasion, we observed an increase in Treg 
infiltration with ADT. This process of adaptive Treg resistance has not previously been 
described in the setting of neo-adjuvant ADT, although increases in Treg density have 
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been observed in response to a range of therapies across a number of tumor types, 
highlighting the notion that adaptive Treg resistance may be a broad-based mechanism 
that can attenuate maximal responses to immunotherapy in patients with diverse 
malignancies.   
 
Interestingly, in both treatment groups, differential gene expression analysis showed that 
degarelix treatment upregulated CHIT1, a marker of macrophage activation shown to 
regulate many inflammatory processes through stimulation of inflammatory mediators 
such as IL8, MMP9, CCL2, CCL5, and CCL11, and correlated with levels of IL-1 and 
TNF29.. Given that macrophages are key antigen-presenting cells, this finding 
corroborates the notion that ADT enhances prostate-antigen presentation and thereby 
promotes prostate-specific T-cell responses. CHIT1 expression appeared to be further 
upregulated by the addition of Cy/GVAX to ADT.  
     
Limitations of this study include the relatively small number of patients in each treatment 
arm and our inability to capture serial immunologic changes within the prostate TME 
over time. We hypothesized that 2 weeks of ADT would be optimal to elicit robust 
immunologic responses, since pre-clinical data suggest that the immunologic effects of 
ADT are transient, with the initial immune infiltrate evolving over time into a more 
suppressive one, dominated by Tregs
18
. The optimal duration of ADT prior to radical 
prostatectomy remains unknown and it is possible that the single dose of degarelix 
acetate used in this study was insufficient to sustain a clinically significant immune 
response. Our study used cyclophosphamide in combination with GVAX based on the 
hypothesis that low-dose cyclophosphamide would be capable of depleting Tregs and 
therefore augmenting an anti-tumor immune response. This approach was supported by 
preclinical studies which showed significant augmentation of anti-tumor immunity upon 
administration of cyclophosphamide approximately 24 hours prior to vaccination with 
GVAX
32,33
. The dosage of cyclophosphamide used here reflects the dosage in a breast 
cancer study that also showed augmentation of anti-tumor immunity with administration 
of cyclophosphamide prior to a GM-CSF secreting vaccine
34
. However, we observed no 
difference in Treg density with the addition of Cy/GVAX to degarelix. One possibility is 
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that the dosing regimen of cyclophosphamide used in this study was not optimal for Treg 
depletion. Since the completion of our study, emerging data showed that oral 
cyclophosphamide may be more effective for Treg depletion
35,36
.  Given these 
limitations, future studies may be required to fully characterize the evolution of the 
immune TME over time and to optimize neoadjuvant immunotherapy in patients with 
prostate cancer. 
 
However, these results do provide important insights into the immunologic effects of 
ADT, either alone or in combination with an allogeneic cell-based vaccine. Importantly, 
the complexity of the immune response to ADT suggests that selectively targeting 
immunosuppressive cell populations may be essential for maximizing the 
immunogenicity of neoadjuvant ADT. The observation that ADT can induce adaptive 
Treg resistance provides a strong rationale for novel strategies aimed at depleting Tregs 
within the prostate TME. Finally, future mechanistic studies aimed at comprehensively 
understanding how androgen deprivation regulates anti-tumor immunity in prostate 
cancer are warranted. 
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Clinical Variable Degarelix (N=15) Degarelix + Cy/GVAX (N=13) 
Median age (interquartile range), years 58 (55-64.5) 61 (54-63) 
Very high risk (%) 6 (40%) 8 (61%) 
Gleason sum, n (%) 
7 6 (40%) 4 (31%) 
8 1 (7%) 2 (15%) 
9 8 (53%) 6 (46%) 
10 0 (0%) 1 (8%) 
T Stage, n (%) 
pT2 4 (27%)  3 (23%) 
pT3a 5 (33%) 6 (46%) 
pT3b 6 (40%) 4 (31%) 
ECOG Status, n (%) 
0 15 (100%) 13 (100%) 
Regional Lymph Node Involvement, n (%) 2 (13%) 3 (23%) 
Positive margin, n (%) 7 (47%) 5 (38%) 
Recurred, n (%) 9 (60%) 4 (31%) 
Developed Metastasis, n (%) 2 (13%) 3 (23%) 
 
Table 1. Patient baseline demographics and disease characteristics. Clinical variables 
for patients treated with degarelix alone versus degarelix plus Cy/GVAX. 
*
Gleason sums 
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 Degarelix (N=15) Degarelix + Cy/GVAX (N=14) 
Adverse Events Grade 1 Grade 2 Grade 3 Grade 1 Grade 2 Grade3 
General Disorders       
Injection-site reaction 10 (66%) 0 0 11 (79%) 2 (14%) 0 
Fatigue 4 (27%) 0 0 3 (21%) 0 0 
Chills 2 (13%)   1 (7%)   
Fever 0 0 0 2 (14%) 0 0 
Flu like symptoms 0 0 0 0 1 (7%) 0 
Malaise 0 0 0 1 (7%) 0 0 
Edema, limbs 1 (7%) 0 0 0 0 0 
Localized Edema 0 0 0 1 (7%) 0 0 
Gastrointestinal Disorders       
Abdominal Pain 2 (13%) 0 0 1 (7%) 0 0 
Nausea 0 0 0 1 (7%) 0 0 
Vascular Disorders       
Hot flashes 6 (40%) 0 0 8 (57%) 0 0 
Reproductive System Disorders       
Erectile dysfunction 1 (7%) 0 0 2 (14%) 0 0 
Testicular disorder 0 0 0 1 (7%) 0 0 
Urinary disorders 0 0 0 0 0 0 
Urinary incontinence 1 (7%) 0 0 1 (7%) 0 0 
Laboratory Abnormalities       
Elevated ALT 1 (7%) 0 0 0 0 1 (7%) 
Elevated AST 2 (13%) 0 0 0 1 (7%) 0 
Skin Disorders       
Rash (systemic) 0 0 0 3 (21%) 2 (14%) 0 
Dizziness 0 0 0 1 (7%) 0 0 
Musculoskeletal Disorders       
Arthralgias 1 (7%) 0 0 2 (14%) 0 0 
Myalgias 1 (7%) 0 0 1 (7%) 0 0 
Nervous System Disorders       
Lethargy 0 0 0 1 (7%) 0 0 
Dizziness 0 0 0 1 (7%) 0 0 
Headache 0 0 0 2 (14%) 0 0 
Ischemia, cerebrovascular 0 0 0 1 (7%) 0 0 
Surgical Complications       
Post-op hematoma (pelvic) 0 0 0 0 1 (7%) 0 
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Table 2. Adverse events reported by treatment group. Adverse events for patients 
treated with degarelix alone versus degarelix plus Cy/GVAX were reported for all 
patients in the study, including one patient in the degarelix plus Cy/GVAX group that 
subsequently went off-study following cerebrovascular ischemia.  
 
Figure 1. Clinical trial design and patient disposition diagram. Patients with high-risk 
localized prostate cancer (T1c–3b N0 M0, Gleason 7–10) were randomized 1:1 to 
degarelix (240 mg SQ) vs. Cyclophosphamide (200 mg/m2 IV) / GVAX (2.5×108 PC3 
cells, 1.6×108 LNCaP cells) given 2 weeks before degarelix. All patients then underwent 
radical prostatectomy 2 weeks after degarelix. Abbreviations: Eastern Cooperative 
Oncology Group (ECOG); subcutaneously (SQ); intravenously (IV). 
 
Figure 2.  Degarelix and degarelix + GVAX increase CD8+ and FOXP3+ T cell 
infitration in prostate tumors. A) Representatitive H&E and immunohistochemistry 
(IHC) for CD8+ T cells, visualized at 4x and 20x magnification B) Representative H&E 
and IHC for FOXP3+ T cells, visualized at 4x and 20x magnification C) Boxplots of 
Log2(CD8+ T cell density), quantified from IHC as represented in Figure 2A. D) 
Boxplots of Log2(FOXP3+ T cell density), quantified from IHC as represented in Figure 
2B. E) Boxplots of the CD8+/FOXP3+ T cell ratio, quantified from IHC as represented 
in Figures 2A and 2B. F) Table of mean CD8+ T cell density (cells/mm
2
), mean Treg 
density (cells/mm
2
), and CD8/Treg ratio for each treatment group and untreated controls, 
with 95% confidence intervals and p-values by Gleason-stratification-adjusted ANOVA 
reported for each comparison of groups; * = p<0.05, ** = p<0.01, and *** = p<0.005   
 
Figure 3. Degarelix and degarelix + Cy/GVAX increase PD-L1 expression in 
prostate tumors. A) Representative IHC for PD-L1, visualized at 4x and 20x 
magnification B) Stacked barplot of %PD-L1 positive cells, showing relative proportion 
of samples with 0% PD-L1 staining, <1% PD-L1 staining, <5% PD-L1 staining, and >5% 
PD-L1 staining in tumor cells in each treatment group and a cohort of untreated matched 
controls.  Distributions of %PD-L1 categories may be visually compared between groups, 
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such that the degarelix + Cy/GVAX group has the highest proportion of samples with 
PD-L1 > 5%. Proportions of samples with %PD-L1 > 0 were also compared between 
groups by Fisher’s exact test, with p-values shown above the plot for each comparison, 
where * = p<0.05, ** = p<0.01, and *** = p<0.005.  
 
Figure 4. Degarelix and degarelix + Cy/GVAX induce complex changes in immune 
gene signatures in primary prostate tumors. A) Differential expression of immune 
related genes by Nanostring Immune Profiling Panel in primary prostate tumors after 
degarelix, degarelix + Cy/GVAX, and untreated matched controls. Euler plots showing 
number of genes with Benjamini-Hochberg corrected t-test p-value < 0.01 for each 
pairwise comparison of groups, such that “up-regulated genes” refers to genes that have 
higher mean frequency in the degarelix + Cy/GVAX group than in the degarelix group 
(cyan), higher mean frequency in the degarelix group than the untreated control group 
(purple), and higher mean frequency in the degarelix + Cy/GVAX group than the 
untreated control group (orange), and “down-regulated genes” refers to genes that have 
lower mean frequency in degarelix + Cy/GVAX vs degarelix (cyan), degarelix vs controls 
(purple), and degarelix + Cy/GVAX vs controls (orange), respectively.  B) Violin-plot of 
log-scaled post-normalization Nanostring gene counts for CHIT1 in each treatment group 
and untreated controls. In Figure 4A, CHIT1 is the sole gene significantly up-regulated in 
each comparison. C) Boxplot of immune cell type absolute abundances as inferred by 
CIBERSORT, colored by treatment group and reported for all samples with CIBERSORT 
p-value<0.05. D) Violin-plot of total immune cell infiltrate for each sample by treatment 
group, such that total immune cell infiltrate represents the sum of CIBERSORT immune 
cell abundances as shown in Figure 4C E) Boxplot of immune cell populations for which 
t-test comparing abundance between groups showed an uncorrected p-value<0.05. P-
values were obtained by unpaired t-test with Benjamini-Hochberg multiple-testing 
correction, and shown on Figures 4B and 4D with * = p<0.05, ** = p<0.01, and *** = 
p<0.005. 
 
Figure 5. Combination of Cy/GVAX with degarelix improves time-to-PSA 
recurrence and increases time-to-next treatment. A) Kaplan-Meier curves comparing 
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time-to-PSA recurrence of patients treated with degarelix + Cy/GVAX vs degarelix alone. 
Informative clinical variables for multivariate analysis were selected by backward feature 
selection using the Akaike Information Criterion. B) Forest plot showing time-to-PSA 
recurrence hazard ratios with 95% confidence interval for multiple cox regression of 
progression-free-survival against Cy/GVAX status, patient age, tumor stage, and Gleason 
score. P-values for each variable are reported, as is the overall log-rank p-value, Akaike 
Information Criterion value, and concordance index for the regression C) Kaplan-Meier 
curves comparing time to next treatment for patients treated with degarelix + Cy/GVAX 
vs degarelix alone, with log-rank p-value reported from multiple cox regression of time-
to-next-treatment against Cy/GVAX status, patient age, tumor stage, and Gleason score. 
Informative clinical variables were selected as in 5A D) Forest plot showing time-to-
next-treatment hazard ratios with 95% confidence interval for multiple cox regression of 
time-to-next-treatment against Cy/GVAX status, patient age, tumor stage, and gleason 
score. P-values for each variable are reported, as is the overall log-rank p-value, Akaike 
Information Criterion value, and concordance index for the regression. 
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